A phase Ib, open-label, clinical trial to evaluate the safety, tolerability and immunogenicity of the Ebola chimpanzee adenovirus vector vaccines, vrc-eboadc069-00-vp (Cad3-Ebo) and vrc-eboadc076-00-vp (Cad3-Eboz), in healthy adults in Kampala, Uganda
Active, not recruitingPACTR201412000957310
US National Institute of Allergy and Infectious Diseases (NIAID)Ebola
Ebola Hemorrhagic Fever
Start: 2015-01-05Target: 90Updated: 2026-09-14